Last updated on July 2019

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis


Brief description of study

Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Clinical Study Identifier: NCT03350815

Find a site near you

Start Over

Novartis Investigative Site

Hagerstown, MD United States
  Connect »